Skip to main content
Erschienen in: Journal of Radiation Oncology 4/2019

01.12.2019 | Original Research

Outcome of surgery and radiotherapy for dermatofibrosarcoma protuberans: 5-year experience from two tertiary centers of eastern India

verfasst von: Anis Bandyopadhyay, Siddhartha Biswas, Harris Mahammad Sepai, Poulami Basu, Arnab Kumar Ghosh

Erschienen in: Journal of Radiation Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

Dermatofibrosarcoma protuberans (DFSP) is a relatively rare cutaneous soft tissue tumor that is locally aggressive, characterized by high rates of local recurrence, but low risk of metastasis. Wide radical excision is the preferred treatment for DFSP, but local recurrence rates of up to 60% after surgery alone have been documented in cases of close or compromised margin. Adjuvant radiotherapy has been used to reduce such recurrences.

Methods

A retrospective audit of patients of DFSP in two tertiary care hospitals of eastern India treated radically by surgery with or without adjuvant radiotherapy was undertaken. A cohort of 16 patients receiving treatment between January 2010 and December 2015 was evaluated for presentation, diagnosis, treatment, local control, toxicity, and disease-free survival.

Results

The mean age of presentation was 46 years with the range from 17 to 71 years, with 9 out of 16 being females. All patients underwent wide local excision except in two cases, with 8 patients undergoing re-resections after initial excision biopsy. A total of 12 out of 16 patients had less than 2-cm margin, and six had close deep resection margin. Of 16 patients, 10 received adjuvant radiotherapy. With the median follow-up of 39 months, four patients have developed recurrence, three in the surgical cohort and one in the radiotherapy cohort. Two patients in the surgical cohort who have developed recurrence had excision with close margin, and use of postoperative radiotherapy in them was withheld in view of increased risk of toxicity.

Conclusion

Combined modality therapy with surgery and radiotherapy for cases of close or inadequate margin results in good local control with acceptable toxicity, in cases where re-surgery is not possible or not contemplated.
Literatur
1.
Zurück zum Zitat Chang CK, Jacobs IA, Salti GI (2004) Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 30:341–345CrossRef Chang CK, Jacobs IA, Salti GI (2004) Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 30:341–345CrossRef
2.
Zurück zum Zitat Mendenhall WM, Zlotecki RA, Scarborough MT (2004) Dermatofibrosarcoma protuberans. Cancer. 101:2503–2508CrossRef Mendenhall WM, Zlotecki RA, Scarborough MT (2004) Dermatofibrosarcoma protuberans. Cancer. 101:2503–2508CrossRef
3.
Zurück zum Zitat Bogucki B, Neuhaus I, Hurst EA (2012) Dermatofibrosarcoma protuberans: a review of the literature. Dermatol Surg Bogucki B, Neuhaus I, Hurst EA (2012) Dermatofibrosarcoma protuberans: a review of the literature. Dermatol Surg
4.
Zurück zum Zitat Lindner NJ, Scarborough MT, Powell GJ, Spanier S, Enneking WF (1999) Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. Eur J Surg Oncol 25:392–397CrossRef Lindner NJ, Scarborough MT, Powell GJ, Spanier S, Enneking WF (1999) Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. Eur J Surg Oncol 25:392–397CrossRef
5.
Zurück zum Zitat Fujimoto M, Kikuchi K, Okochi H, Furue M (1998) Atrophic dermatofibrosarcoma protuberans: a case report and review of the literature. Dermatology 196:422–424CrossRef Fujimoto M, Kikuchi K, Okochi H, Furue M (1998) Atrophic dermatofibrosarcoma protuberans: a case report and review of the literature. Dermatology 196:422–424CrossRef
6.
Zurück zum Zitat MacKie RM (1992) Soft tissue tumors. In: Champion RH, Burton JL, Ebling FJG (eds) Textbook of dermatology, 5th edn. Blackwell, London, pp 2073–2100 MacKie RM (1992) Soft tissue tumors. In: Champion RH, Burton JL, Ebling FJG (eds) Textbook of dermatology, 5th edn. Blackwell, London, pp 2073–2100
7.
Zurück zum Zitat Ratner D, Thomas CO, Johnson TM, Sondak VK, Hamilton TA, Nelson BR, Swanson NA, Garcia C, Clark RE, Grande DJ (1997) Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 37:600–613CrossRef Ratner D, Thomas CO, Johnson TM, Sondak VK, Hamilton TA, Nelson BR, Swanson NA, Garcia C, Clark RE, Grande DJ (1997) Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 37:600–613CrossRef
8.
Zurück zum Zitat Sun LM, Wang CJ, Huang CC, Leung SW, Chen HC, Fang FM, Huang EY, Lee SP (2000) Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 57:175–181CrossRef Sun LM, Wang CJ, Huang CC, Leung SW, Chen HC, Fang FM, Huang EY, Lee SP (2000) Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 57:175–181CrossRef
9.
Zurück zum Zitat Dagan R, Morris CG, Zlotecki RA, Scarborough MT, Mendenhall WM (2005) Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol 28(6):537–539CrossRef Dagan R, Morris CG, Zlotecki RA, Scarborough MT, Mendenhall WM (2005) Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol 28(6):537–539CrossRef
10.
Zurück zum Zitat Williams N, Morris CG, Kirwan JM, Dagan R, Mendenhall WM (2014) Radiotherapy for Dermatofibrosarcoma Protuberans. Am J Clin Oncol 37(5):430–432CrossRef Williams N, Morris CG, Kirwan JM, Dagan R, Mendenhall WM (2014) Radiotherapy for Dermatofibrosarcoma Protuberans. Am J Clin Oncol 37(5):430–432CrossRef
11.
Zurück zum Zitat Joiner MC, Van der Kogel AJ (1997) The linear quadratic approach to fractionation and calculation of iso effect relationships. In: Steel GG (ed) Basic clinical radiobiology. Oxford University Press, New York, pp 106–112 Joiner MC, Van der Kogel AJ (1997) The linear quadratic approach to fractionation and calculation of iso effect relationships. In: Steel GG (ed) Basic clinical radiobiology. Oxford University Press, New York, pp 106–112
12.
Zurück zum Zitat Enzinger FM, Weiss SW (1988) Fibrohistiocytic tumors of intermediate malignancy. In: Stamathis G (ed) Soft tissue tumors. Mosby, St. Louis, pp 252–268 Enzinger FM, Weiss SW (1988) Fibrohistiocytic tumors of intermediate malignancy. In: Stamathis G (ed) Soft tissue tumors. Mosby, St. Louis, pp 252–268
13.
Zurück zum Zitat Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, Brennan MF, Lewis JJ (2000) Dermatofibrosarcoma protuberans. A clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 88:2711–2720CrossRef Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, Brennan MF, Lewis JJ (2000) Dermatofibrosarcoma protuberans. A clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 88:2711–2720CrossRef
14.
Zurück zum Zitat Rutgers EJ, Kroon BB, Albus-Lutter CE, Gortzak E (1992) Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 18:241–248 Rutgers EJ, Kroon BB, Albus-Lutter CE, Gortzak E (1992) Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 18:241–248
15.
Zurück zum Zitat Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG, Gronchi A (2005) Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 23:7669–7675CrossRef Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG, Gronchi A (2005) Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 23:7669–7675CrossRef
16.
Zurück zum Zitat Fields RC, Hameed M, Qin LX, Moraco N, Jia X, Maki RG, Singer S, Brennan MF (2011) Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol 18:328–336CrossRef Fields RC, Hameed M, Qin LX, Moraco N, Jia X, Maki RG, Singer S, Brennan MF (2011) Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol 18:328–336CrossRef
17.
Zurück zum Zitat Farma JM, Ammori JB, Zager JS, Marzban SS, Bui MM, Bichakjian CK, Johnson TM, Lowe L, Sabel MS, Wong SL, Douglas Letson G, Messina JL, Cimmino VM, Sondak VK (2010) Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol 17:2112–2118CrossRef Farma JM, Ammori JB, Zager JS, Marzban SS, Bui MM, Bichakjian CK, Johnson TM, Lowe L, Sabel MS, Wong SL, Douglas Letson G, Messina JL, Cimmino VM, Sondak VK (2010) Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol 17:2112–2118CrossRef
18.
Zurück zum Zitat Castle KO, Guadagnolo BA, Tsai CJ, Feig BW, Zagars GK Dermatofibrosarcoma Protuberans: Long-term Outcomes of 53 Patients Treated With Conservative Surgery and Radiation Therapy. Int J Radiat Oncol Biol Phys 86(3):585–590CrossRef Castle KO, Guadagnolo BA, Tsai CJ, Feig BW, Zagars GK Dermatofibrosarcoma Protuberans: Long-term Outcomes of 53 Patients Treated With Conservative Surgery and Radiation Therapy. Int J Radiat Oncol Biol Phys 86(3):585–590CrossRef
19.
Zurück zum Zitat Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB (2004) Dermatofibrosarcoma Protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer. 101(1):28–38CrossRef Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB (2004) Dermatofibrosarcoma Protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer. 101(1):28–38CrossRef
20.
Zurück zum Zitat Sondak VK, Cimmino VM, Lowe LM, Dubay DA (1999) JohnsonTM. Dermatofibrosarcoma protuberans: what is the best surgical approach? Surg Oncol 8:183–189CrossRef Sondak VK, Cimmino VM, Lowe LM, Dubay DA (1999) JohnsonTM. Dermatofibrosarcoma protuberans: what is the best surgical approach? Surg Oncol 8:183–189CrossRef
21.
Zurück zum Zitat Ballo MT, Zagars GK, Pisters P, Pollack A (1998) The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 40(4):823–827CrossRef Ballo MT, Zagars GK, Pisters P, Pollack A (1998) The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 40(4):823–827CrossRef
22.
Zurück zum Zitat Mukherji A, Sinnatamby M (2017) Malignant soft tissue sarcoma of the shoulder treated by surface mould brachytherapy boost in an adjuvant setting. J Contemp Brachytherapy 9(2):167–173CrossRef Mukherji A, Sinnatamby M (2017) Malignant soft tissue sarcoma of the shoulder treated by surface mould brachytherapy boost in an adjuvant setting. J Contemp Brachytherapy 9(2):167–173CrossRef
23.
Zurück zum Zitat Bandyopadhyay A, Basu P, Biswas S, Ghosh S Dermatofibrosarcoma protruberans of the scalp treated with customised surface mould high-dose-rate (HDR) brachytherapy: a case report. J Radiother Pract 17(4):455–459CrossRef Bandyopadhyay A, Basu P, Biswas S, Ghosh S Dermatofibrosarcoma protruberans of the scalp treated with customised surface mould high-dose-rate (HDR) brachytherapy: a case report. J Radiother Pract 17(4):455–459CrossRef
24.
Zurück zum Zitat McArthur GA, Demetri GD, van Oosterom A et al (2005) Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23:866–873CrossRef McArthur GA, Demetri GD, van Oosterom A et al (2005) Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23:866–873CrossRef
25.
Zurück zum Zitat Han A, Chen EH, Niedt G et al (2009) Neoadjuvant Imatinib therapy for Dermatofibrosarcoma Protuberans. Arch Dermatol 145(7):792–796CrossRef Han A, Chen EH, Niedt G et al (2009) Neoadjuvant Imatinib therapy for Dermatofibrosarcoma Protuberans. Arch Dermatol 145(7):792–796CrossRef
26.
Zurück zum Zitat Misset J, Kerob D, Porcher R et al (2007) Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: result of a multicentric phase II study on 25 patients. J Clin Oncol 25(18S):10032CrossRef Misset J, Kerob D, Porcher R et al (2007) Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: result of a multicentric phase II study on 25 patients. J Clin Oncol 25(18S):10032CrossRef
27.
Zurück zum Zitat DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK (2004) Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 100(5):1008–1016CrossRef DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK (2004) Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 100(5):1008–1016CrossRef
Metadaten
Titel
Outcome of surgery and radiotherapy for dermatofibrosarcoma protuberans: 5-year experience from two tertiary centers of eastern India
verfasst von
Anis Bandyopadhyay
Siddhartha Biswas
Harris Mahammad Sepai
Poulami Basu
Arnab Kumar Ghosh
Publikationsdatum
01.12.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 4/2019
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-020-00412-4

Weitere Artikel der Ausgabe 4/2019

Journal of Radiation Oncology 4/2019 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.